Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice

Journal of Pathology

Volumn 191, Issue 2, 2000, Pages 193-201

  Di Carlo, Emma ^a   Meazza, Raffaella ^b,c   Basso, Stefania ^b   Rosso, Ombretta ^b   Comes, Alberto ^b   Gaggero, Alessia ^b   Musiani, Piero ^a   Santi, Leonardo ^b,c   Ferrini, Silvano ^b,d  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Gene transfer; IL 15; IL 2; NK cells 202 207; NSCLC; Nude mice

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; MONOCYTE CHEMOTACTIC PROTEIN;

ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; GENE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; XENOTRANSPLANTATION;

ANIMALS; CARCINOMA, SMALL CELL; CHEMOKINE CCL2; FEMALE; GENE TRANSFER TECHNIQUES; GENES, MHC CLASS I; GRAFT REJECTION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MACROPHAGE INFLAMMATORY PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0034039557     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200006)191:2<193::AID-PATH602>3.0.CO;2-4     Document Type: Article

References (43)

1. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
2. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T cell responses. Immunol Today 1998; 19: 153-157.
3. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
4. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumors on. Immunol Today 1997; 18: 292-299.
5. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus downregulation in melanoma cell lines. J Immunol 1994; 153: 1225-1233.
6. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 340-347.
7. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
8. Traversari C, Meazza R, Coppolecchia M, et al. IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 1997; 4: 1029-1035.
9. Doyle A, Martin MJ, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985; 161: 1135-1151.
10. Storkus WJ, Alexander S, Payne JA, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I genes. Proc Natl Acad Sci U S A 1989; 86: 2361-2364.
11. Trinchieri G. Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 1994; 180: 417-421.
12. Moretta A, Biassoni R, Bottino C, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997; 155: 105-117.
13. Long EO, Burshtyn DN, Clark WP, et al. Killer cell inhibitory receptors: diversity, specificity and function. Immunol Rev 1997; 155: 135-144.
14. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221-244.
15. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 1994; 264: 965-967.
16. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the 1L-2 receptor. J Exp Med 1994; 180: 1395-1403.
17. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2632-3640.
18. Munger W, De Joy SQ, Jeyaseelan RS, et al. Studies evaluating the anti-tumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995; 165: 289-293.
19. Ferrini S, Azzarone B, Jasmin C. Is IL-15 a suitable candidate for cancer gene therapy? Gene Ther 1996; 3: 656-657.
20. Meazza R, Verdiani S, Biassoni R, et al. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 1996; 12: 2187-2192.
21. Meazza R, Gaggero A, Negua F, et al. Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides. Eur J Immunol 1997; 27: 1049-1054.
22. Tagaya Y, Bamford RN, De Filippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signalling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329-336.
23. Meazza R, Marciano S, Sforzini S, et al. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transaction in small-cell lung cancer. Br J Cancer 1996; 74: 788-795.
24. Ferrini S, Biassoni R, Moretta A, et al. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T cell clones capable of lysing autologous carcinoma cells. Int J Cancer 1985; 36: 337-343.
25. Vecchi A, Garlanda C, Lampugnani MG, et al. Monoclonal antibodies specific in the identification of adult and embryonic endothelium. Eur J Cell Biol 1994; 63: 247-254.
26. Giovarelli M, Santoni A, Jemma C, et al. Obligatory role of interferon-gamma in induction of lymphokine activated and T-lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol 1988; 141: 2831-2836.
27. Angiolillo AL, Kanegane H, Sgaoari C, et al. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997; 233: 231-237.
28. Di Carlo E, Coletti A, Modesti A, et al. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro-and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw 1998; 9: 61-68.
29. Allavena P, Giardina G, Bianchi G, Mantovani A. IL-15 is chemotactic for natural killer cells and stimulates their adhesion to vascular endothelium. J Leukoc Biol 1997; 61: 729-735.
30. Oppenheim JJ, Zacharie COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene 'Intercrine' cytokine family. Annu Rev Immunol 1991; 9: 617-648.
31. Badolato R, Ponzi AN, Millesimo M, et al. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 1997; 90: 2804-2809.
32. Wei S, Liu JH, Blanchard DK, Djeu JY. Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2. J Immunol 1994; 152: 3630-3636.
33. Brozna JP. Shwartzman reaction. Semin Thromb Hemost 1990; 16: 326-332.
34. Bender JR, Pardi R, Karasek MA, Engelman EG. Phenotypic and functional characterization of lymphocytes that bind human microvascular endothelial cells in vitro. J Clin Invest 1987; 79: 1979-1988.
35. Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin-2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987; 138: 1779-1785.
36. Musiani P, Modesti A, Giovarelli M, et al. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol Today 1997; 18: 32-36.
37. Di Carlo E, Modesti A, Coletti A, et al. Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4-or an IL5-transduced tumour. J Pathol 1998; 186: 390-397.
38. Stevens P, Piazza DE. Interleukin-2 increases the oxidative activity and induces migration of murine polymorphonuclear leukocytes in vivo. Int J Immunopharmacol 1990; 12: 605-614.
39. Mori A, Suko K, Kaminuma O, et al. IL-15 promotes cytokine production of human T helper cells. J Immunol 1996; 156: 2400-2405.
40. Alleva DG, Kaser SB, Monroy MA, et al. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production. J Immunol 1997; 159: 2941-2951.
41. Hicks C, Cooley MA, Penny R. Investigation of interleukin-2 receptors on human endothelial cells. Growth factors 1990; 5: 201-208.
42. Frazier Scott K, Hatzakis H, Seong D, et al. Influence of natural and recombinant interleukin-2 on endothelial cell arachidonate metabolism. J Clin Invest 1988; 82: 1877-1883.
43. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999; 96: 3957-3962.